PainReform's Shares Tumble After Data Issue Muddles Late-Stage Study of Non-Opioid Pain Treatment

MT Newswires Live11-20

PainReform's (PRFX) shares tumbled nearly 27% Wednesday after the specialty pharmaceuticals company blamed an "incoherence of data" for unclear results in the latter portion of a phase 3 trial evaluating its PRF-110 drug candidate as a non-opioid alternative treatment for post-surgical pain.

Topline data from the late-stage study obtained by Lotus Clinical Research, a contract research organization hired by PainReform, indicates the company's extended-release formulation of a widely used local anesthetic showed statistically significant superiority in reducing pain during the first 48 hours following bunionectomy procedures, compared with patients treated with a placebo, the company said.

But data from the subsequent 24-hour period, essential for evaluating the primary endpoint of the trial, was unclear. PainReform said it is working with Lotus to complete the analysis of that portion of the data, adding, "At present, there can be no assurance that the effort to resolve the incoherence will be successful."

Price: 1.02, Change: -0.38, Percent Change: -26.93

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment